Lack of Clinical Benefit of Interferon β-1a Among Patients With Severe Acute Respiratory Distress Syndrome: Time to Overhaul Drug Trials in ARDS?

doi:10.1001/jama.2019.22524

Editorial

. 2020 Feb 25;323(8):713-715.

doi: 10.1001/jama.2019.22524.

Lack of Clinical Benefit of Interferon β-1a Among Patients With Severe Acute Respiratory Distress Syndrome: Time to Overhaul Drug Trials in ARDS?

Manu Shankar-Hari^{1

2}, Carolyn S Calfee³

Affiliations

¹ School of Immunology and Microbial Science, Kings College London, London, United Kingdom.
² Guy's and St Thomas' NHS Foundation Trust, ICU Support Offices, St Thomas' Hospital, London, United Kingdom.
³ Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, Departments of Medicine and Anesthesia and Cardiovascular Research Institute, University of California, San Francisco.

PMID: 32065830
DOI: 10.1001/jama.2019.22524

Editorial

Lack of Clinical Benefit of Interferon β-1a Among Patients With Severe Acute Respiratory Distress Syndrome: Time to Overhaul Drug Trials in ARDS?

Manu Shankar-Hari et al. JAMA. 2020.

. 2020 Feb 25;323(8):713-715.

doi: 10.1001/jama.2019.22524.

Authors

Manu Shankar-Hari^{1

2}, Carolyn S Calfee³

Affiliations

¹ School of Immunology and Microbial Science, Kings College London, London, United Kingdom.
² Guy's and St Thomas' NHS Foundation Trust, ICU Support Offices, St Thomas' Hospital, London, United Kingdom.
³ Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, Departments of Medicine and Anesthesia and Cardiovascular Research Institute, University of California, San Francisco.

PMID: 32065830
DOI: 10.1001/jama.2019.22524

No abstract available

PubMed Disclaimer

Comment on

Effect of Intravenous Interferon β-1a on Death and Days Free From Mechanical Ventilation Among Patients With Moderate to Severe Acute Respiratory Distress Syndrome: A Randomized Clinical Trial.
Ranieri VM, Pettilä V, Karvonen MK, Jalkanen J, Nightingale P, Brealey D, Mancebo J, Ferrer R, Mercat A, Patroniti N, Quintel M, Vincent JL, Okkonen M, Meziani F, Bellani G, MacCallum N, Creteur J, Kluge S, Artigas-Raventos A, Maksimow M, Piippo I, Elima K, Jalkanen S, Jalkanen M, Bellingan G; INTEREST Study Group. Ranieri VM, et al. JAMA. 2020 Feb 25;323(8):725-733. doi: 10.1001/jama.2019.22525. JAMA. 2020. PMID: 32065831 Clinical Trial.

Cited by

Acute respiratory distress syndrome.
Meyer NJ, Gattinoni L, Calfee CS. Meyer NJ, et al. Lancet. 2021 Aug 14;398(10300):622-637. doi: 10.1016/S0140-6736(21)00439-6. Epub 2021 Jul 1. Lancet. 2021. PMID: 34217425 Free PMC article. Review.
Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review.
Cortegiani A, Ippolito M, Greco M, Granone V, Protti A, Gregoretti C, Giarratano A, Einav S, Cecconi M. Cortegiani A, et al. Pulmonology. 2021 Jan-Feb;27(1):52-66. doi: 10.1016/j.pulmoe.2020.07.003. Epub 2020 Jul 20. Pulmonology. 2021. PMID: 32713784 Free PMC article.

Publication types

Actions
Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

Grants and funding

R35 HL140026/HL/NHLBI NIH HHS/United States

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Lack of Clinical Benefit of Interferon β-1a Among Patients With Severe Acute Respiratory Distress Syndrome: Time to Overhaul Drug Trials in ARDS?

Affiliations

Lack of Clinical Benefit of Interferon β-1a Among Patients With Severe Acute Respiratory Distress Syndrome: Time to Overhaul Drug Trials in ARDS?

Authors

Affiliations

Comment on

Similar articles

Cited by

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical